Sequana Medical NV announced the appointment of Alexandra Clyde as an independent Non-Executive Director of the company. Ms. Clyde is a highly experienced global business executive with an exceptional understanding and track record of successfully navigating health economics and reimbursement in the medical device industry. The Company also announced that Erik Amble will step down as a member of the Board of Directors after the board meeting of 7 September 2022, and will continue to attend the meetings as a board observer in a non-voting capacity.

Ms. Clyde is Senior Vice President of Global Health Economics, Policy, and Reimbursement for Medtronic plc. In this role, she leads a global function of more than 300 reimbursement and health economics professionals and provides company-wide leadership on health and payment policy. She is a member of the Duke Margolis Value-Based Payment and Innovative Technology Consortium, the Health Technology Assessment International (HTAi) Policy Forum, and the Advisory Board for the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center.

She is a former member of the Health Care Payment Learning and Action Network's (HCP-LAN) Guiding Committee which is charged by the US Secretary of Health and Human Services with accelerating the health care system's transition to alternative payment models (APMs) by combining the innovation, power, and reach of the public and private sectors. She has also participated in various Centers for Medicare and Medicaid Services (CMS) technical advisory councils as well as other private and public sector initiatives to improve value in health care. Alex graduated from Colgate University with a B.A. in Economics and from Harvard University with a M.S. in Health Policy and Management.

The appointment of Ms. Clyde is subject to the approval of the Board of Directors and will also be submitted for approval to the Company's next Meeting of Shareholders. Her appointment is effective as of 25 August 2022.
.